MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Capricor Therapeutics Inc

Gesloten

9.17 -5.37

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.68

Max

9.62

Belangrijke statistieken

By Trading Economics

Inkomsten

5.4M

-7.1M

Verkoop

8.9M

11M

EPS

-0.16

Winstmarge

-63.938

Werknemers

160

EBITDA

5.3M

-7.3M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+347.64% upside

Dividenden

By Dow Jones

Volgende Winsten

12 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-60M

526M

Vorige openingsprijs

14.54

Vorige sluitingsprijs

9.17

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Capricor Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mrt 2025, 15:41 UTC

Belangrijke Marktbewegers

Capricor Therapeutics Shares Rise on FDA Priority Review

Peer Vergelijking

Prijswijziging

Capricor Therapeutics Inc Prognose

Koersdoel

By TipRanks

347.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43.6 USD  347.64%

Hoogste 77 USD

Laagste 25 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Capricor Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Technische score

By Trading Central

9.48 / 11.81Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Capricor Therapeutics Inc

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.